ST. LOUIS--(BUSINESS WIRE)--Certara™, a Vector Capital portfolio company and a leading provider of drug discovery and development software and scientific consulting services, today announced the completion of its acquisition of UK-based Simcyp Limited. Simcyp is a leading research company providing a modeling and simulation platform for predicting the fate of drugs in virtual populations, including pediatric populations. The now completed acquisition means Simcyp’s highly-regarded technologies will be integrated into planned Certara translational science initiatives.
